Between-year differences in fracture risk reductions over the Spinal Osteoporosis Therapeutic Intervention study period, suggesting a potential waning of antifracture effect over time.Nevertheless, year-by-year analyses have not been published for any of these therapies and no conclusions Bicalutamide can be drawn about potential loss of efficacy associated with suboptimal adherence. Zoledronic acid is a bisphosphonate that is administered once yearly, by intravenous infusion. The antifracture efficacy of zoledronic acid has been demonstrated in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial and the HORIZON Recurrent Fracture Trial, which showed that zoledronic acid 5 mg significantly reduced fracture risk in postmenopausal women with osteoporosis and in men and women with prior low-trauma hip fracture.
However, neither of these studies investigated the time-to-onset or the year-by-year antifracture effect of zoledronic acid. This analysis pooled data from all Kinetin inhibitor female patients in the HORIZON-PFT and -RFT to examine the time-to-onset of antifracture efficacy with zoledronic acid and to evaluate the persistence of this effect, by analyzing the incidence of clinical fractures within each year of treatment. Methods Study design and patients We performed a pooled post-hoc analysis of data from all women who were randomized in the multinational randomized, double-blind, placebo-controlled HORIZON-PFT and HORIZON RFT. Full methods have been published previously but are summarized here in brief.
The HORIZON-PFT enrolled postmenopausal women aged 65–89 years who had either a femoral neck radiological evidence of at least two mild or one moderate vertebral fracture at baseline. HORIZON-RFT Ariflo 153259-65-5 enrolled patients aged ..50 years who had undergone surgical repair of a hip fracture that had been sustained with minimal trauma a fall from in the previous buy Patupilone 90 days. Previous use of bisphosphonates with sufficient washout was permitted. In each study, patients received a 15-minute intravenous infusion of zoledronic acid 5 mg or placebo. In the HORIZON-PFT, treatments were administered at baseline, 12 and 24 months, and patients monitored for a total of 3 years. In the HORIZON-RFT, treatments were administered within 90 days after surgical repair of the hip fracture and every 12 months thereafter for the duration of the study (median duration of follow-up, 1.
9 years). Patients also received supplemental calcium and vitamin D for the duration of the trial in which they were enrolled. Both studies were reviewed by the Independent achieved status Ethics Committee or Institutional Review Board at each participating centre and were conducted according to the ethical principles of the The endpoints of the persistence of effect analysis were the year-by-year incidence of these three fracture types over 3 years. Criteria for fracture classification have been defined previously. Year-by-year incidence of morphometric vertebral fractures was also analysed for patients in the HORIZON-PFT. Definition of an incident morphometric vertebral fracture was described previously. Kaplan-Meier analysis was used to determine the cumulative proportion of patients with each type of fracture at individual timepoints. A Cox proportional hazards regression model, stratified by study was used to determine the statistical significance at each timepoint of the between-treatment difference in the cumulative incidence of each category of fracture.
Related posts: